BOSTON, MA — August 13, 2025 — Beechinor, BiotechReporter.news — Compass Therapeutics Inc. (Nasdaq: CMPX) has announced the pricing of its underwritten public offering of 33,290,000 shares of common stock at $3.00 per share, along with pre-funded warrants to purchase up to 6,710,000 shares at $2.9999 per warrant.
The offering is expected to generate gross proceeds of approximately $120 million for Compass, before deducting underwriting discounts, commissions, and other expenses. The offering is expected to close around August 14, 2025, contingent upon customary closing conditions. Underwriters have been granted a 30-day option to purchase up to 6,000,000 additional shares of common stock at the public offering price, less the underwriting discount.
Compass plans to use the net proceeds to prepare for commercial readiness, fund research and clinical development, and for general corporate purposes.
Jefferies, Piper Sandler and Guggenheim Securities are acting as joint active bookrunning managers. Raymond James, Wedbush PacGrow and H.C. Wainwright & Co. are acting as lead managers. Ladenburg Thalmann and D. Boral Capital are acting as co-managers.
The offering is made via a written prospectus and prospectus supplement, part of a registration statement filed with the SEC. The preliminary prospectus supplement is available on the SEC’s website.
Anna Gifford, Chief of Staff, media@compasstherapeutics.com, 617-500-8099
Source: Compass Therapeutics, Inc.
